211 related articles for article (PubMed ID: 11086633)
1. Blocking the tissue renin-angiotensin system: the future cornerstone of therapy.
Unger T; Azizi M; Belz GG
J Hum Hypertens; 2000 Oct; 14 Suppl 2():S23-31. PubMed ID: 11086633
[TBL] [Abstract][Full Text] [Related]
2. Persistent cardiovascular effects of chronic renin-angiotensin system inhibition following withdrawal in adult spontaneously hypertensive rats.
Paull JR; Widdop RE
J Hypertens; 2001 Aug; 19(8):1393-402. PubMed ID: 11518847
[TBL] [Abstract][Full Text] [Related]
3. Putting the efficacy of candesartan cilexetil into perspective: a review of new comparative data.
Mallion JM; Badguet JP
J Hum Hypertens; 2000 Oct; 14 Suppl 2():S33-41. PubMed ID: 11086634
[TBL] [Abstract][Full Text] [Related]
4. Renal responses to angiotensin receptor antagonist and angiotensin-converting enzyme inhibitor in partially nephrectomized spontaneously hypertensive rats.
Okada H; Suzuki H; Kanno Y; Ikenaga H; Saruta T
J Cardiovasc Pharmacol; 1995 Oct; 26(4):564-9. PubMed ID: 8569216
[TBL] [Abstract][Full Text] [Related]
5. Comparison of type 1 angiotensin II receptor blockers and angiotensin converting enzyme inhibitors in the treatment of hypertension.
Weber MA
J Hypertens Suppl; 1997 Dec; 15(6):S31-6. PubMed ID: 9493125
[TBL] [Abstract][Full Text] [Related]
6. Acute effects of candesartan cilexetil (the new angiotensin II antagonist) on systemic and renal haemodynamics in hypertensive patients.
Fridman K; Andersson OK; Wysocki M; Friberg P; Sunzel M
Eur J Clin Pharmacol; 1998 Sep; 54(7):497-501. PubMed ID: 9832289
[TBL] [Abstract][Full Text] [Related]
7. Protective effects of candesartan cilexetil (TCV-116) against stroke, kidney dysfunction and cardiac hypertrophy in stroke-prone spontaneously hypertensive rats.
Inada Y; Wada T; Ojima M; Sanada T; Shibouta Y; Kanagawa R; Ishimura Y; Fujisawa Y; Nishikawa K
Clin Exp Hypertens; 1997 Oct; 19(7):1079-99. PubMed ID: 9310205
[TBL] [Abstract][Full Text] [Related]
8. Pharmacologic properties of candesartan cilexetil--possible mechanisms of long-acting antihypertensive action.
Inada Y; Ojima M; Kanagawa R; Misumi Y; Nishikawa K; Naka T
J Hum Hypertens; 1999 Jan; 13 Suppl 1():S75-80. PubMed ID: 10076925
[TBL] [Abstract][Full Text] [Related]
9. Regional hemodynamic effects of candesartan cilexetil (TCV-116), an angiotensin II AT1-receptor antagonist, in conscious spontaneously hypertensive rats.
Kanagawa R; Wada T; Sanada T; Ojima M; Inada Y
Jpn J Pharmacol; 1997 Mar; 73(3):185-90. PubMed ID: 9127812
[TBL] [Abstract][Full Text] [Related]
10. Key features of candesartan cilexetil and a comparison with other angiotensin II receptor antagonists.
Sever PS
J Hum Hypertens; 1999 Jan; 13 Suppl 1():S3-10; discussion S33-4. PubMed ID: 10076915
[TBL] [Abstract][Full Text] [Related]
11. [Candesartan cilexetil: pharmacological properties and protective effects against organ damage of a novel nonpeptide angiotensin II-receptor antagonist].
Inada Y; Naka T
Nihon Yakurigaku Zasshi; 2000 Mar; 115(3):151-60. PubMed ID: 10876800
[TBL] [Abstract][Full Text] [Related]
12. Angiotensin II receptor blockers. A new class of antihypertensive drugs.
Velasquez MT
Arch Fam Med; 1996 Jun; 5(6):351-6. PubMed ID: 8640326
[TBL] [Abstract][Full Text] [Related]
13. Comparison of the antihypertensive effects of the new angiotensin II (AT1) receptor antagonist candesartan cilexetil (TCV-116) and the angiotensin converting enzyme inhibitor enalapril in rats.
Wada T; Inada Y; Ojima M; Sanada T; Shibouta Y; Nishikawa K
Hypertens Res; 1996 Jun; 19(2):75-81. PubMed ID: 10968199
[TBL] [Abstract][Full Text] [Related]
14. Effects of AT1 receptor blockade on blood pressure and the renin-angiotensin system in spontaneously hypertensive rats of the stroke prone strain.
Wagner J; Drab M; Bohlender J; Amann K; Wienen W; Ganten D
Clin Exp Hypertens; 1998 Feb; 20(2):205-21. PubMed ID: 9533614
[TBL] [Abstract][Full Text] [Related]
15. Comparative effects of three sites of renin-angiotensin blockade on the regression of left ventricular hypertrophy in spontaneously hypertensive rats.
Zhang Q; Kohara K; Qui HY; Hiwada K
Am J Ther; 1997; 4(5-6):199-202. PubMed ID: 10423611
[TBL] [Abstract][Full Text] [Related]
16. Role of the renin-angiotensin system in hypertension in the elderly.
Nagano M; Higaki J; Mikami H; Ogihara T
Blood Press Suppl; 1994; 5():130-3. PubMed ID: 7889195
[TBL] [Abstract][Full Text] [Related]
17. Angiotensin II receptor antagonism: losartan - sites and mechanisms of action.
Triggle DJ
Clin Ther; 1995; 17(6):1005-30. PubMed ID: 8750395
[TBL] [Abstract][Full Text] [Related]
18. Involvement of angiotensin II in progression of renal injury in rats with genetic non-insulin-dependent diabetes mellitus (Wistar fatty rats).
Noda M; Matsuo T; Nagano-Tsuge H; Ohta M; Sekiguchi M; Shibouta Y; Naka T; Imura Y
Jpn J Pharmacol; 2001 Apr; 85(4):416-22. PubMed ID: 11388646
[TBL] [Abstract][Full Text] [Related]
19. Combined blockade of AT1-receptors and ACE synergistically potentiates antihypertensive effects in SHR.
Raasch W; Jöhren O; Schwartz S; Gieselberg A; Dominiak P
J Hypertens; 2004 Mar; 22(3):611-8. PubMed ID: 15076168
[TBL] [Abstract][Full Text] [Related]
20. Involvement of angiotensin II in cardiovascular and renal injury: effects of an AT1-receptor antagonist on gene expression and the cellular phenotype.
Kim S; Iwao H
J Hypertens Suppl; 1997 Dec; 15(6):S3-7. PubMed ID: 9493120
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
